BCL-2 family proteins: The mitochondrial apoptotic key regulators

Current Cancer Therapy Reviews

Volumn 8, Issue 2, 2012, Pages 133-140

  Daisy, P ^a   Saipriya, K ^a  

^a HOLY CROSS COLLEGE   (India)

Author keywords

Apoptosis; Bcl 2 family; BH 3 domain; Molecular pathways; Small molecule inhibitors

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; APOPTOSOME; BH3 PROTEIN; BIM PROTEIN; CASPASE 2; CHELERYTHRINE; CYTOCHROME C; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FAS ANTIGEN; GOSSYPOL; NAVITOCLAX; OBATOCLAX; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; PUMA PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR 1;

APOPTOSIS; CELL DAMAGE; CELL FATE; CELL NUCLEUS; CELL STRESS; CELL SURVIVAL; CYTOPLASM; CYTOSOL; DRUG EFFICACY; DRUG PROTEIN BINDING; ENZYME ACTIVATION; EXTRACELLULAR SPACE; LIGAND BINDING; MALIGNANT TRANSFORMATION; MITOCHONDRIA OUTER MEMBRANE PERMEABILIZATION; MITOCHONDRIAL PERMEABILITY; MITOCHONDRION; OLIGOMERIZATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION;

EID: 84861766071     PISSN: 15733947     EISSN: 18756301     Source Type: Journal    
DOI: 10.2174/157339412800675414     Document Type: Review

References (81)

1. Jin S, Di Paola RS, Mathew R, White E. Metabolic catastrophe as a means to cancer cell death. J Cell Sci 2007; 120: 379-83.
2. Brown GD. Sensing necrosis with mincle. Nat immunol 2008; 9: 1099-100.
3. Jones AM. Programmed cell death in development and defense. Plant physiol 2001; 125: 94-7.
4. Kerr JF, Winterford CM, Harmon BV. Apoptosis: Its significance in cancer and cancer therapy. Cancer 1994; 73: 2013-26.
5. Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the bcl-2 family and cell death (review). Blood 1996; 88: 386-401.
6. Ishizaki Y, Cheng L, Mudge AW, Raff MC. Programmed cell death by default in embryonic cells, fibroblasts, and cancer cells. Mol Biol Cell 1995; 6: 1443-58.
7. Weil M, Jacobson MD, Coles HS, et al. Constitutive expression of the machinery for programmed cell death. J Cell Biol 1996; 133: 1053-9.
8. Zapata JM, Pawlowski K, Haas E. A diverse family of proteins containing tumor necrosis factor receptor-associated factor domains. J Biol Chem 2001; 276: 24242-52.
9. Reed JC, Pellecchia M. Apoptosis-based therapies for hematologic malignancies (review) [119 refs]. Blood 2005; 106: 408-18.
10. Li P, Nijhawan D, Budihardjo I. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91: 479-89.
11. Ahmad M, Srinivasula SM, Hegde R, Mukattash R, Fernandes-Alnemri T, Alnemri ES. Identification and characterization of murine caspase-14, a new member of the caspase family. Cancer Res 1998; 58: 5201-5.
12. Thornberry NA, Lazebnik Y. Caspases: enemies within. Sci 1998; 281: 1312-6.
13. Nicholson DW, Thornberry NA. Caspases: killer proteases. Trends Biochem Sci 1997; 22: 299-306.
14. Degterev A, Boyce M, Yuan J. A decade of caspases. Oncogene 2003; 22: 8543-67.
15. Walczak H, Krammer PH. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res 2000; 256: 58-66.
16. Naismith JH, Sprang SR. Modularity in the TNF-receptor family. Trends Biochem Sci 1998; 23: 74-9.
17. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000; 256: 42-9.
18. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev 2001; 15: 2922-33.
19. Acehan D, Jiang X, Morgan DG, Heuser JE, Wang X, Akey CW. Three-dimensional structure of the apoptosome: implications for assembly, procaspase-9 binding and activation. Mol Cell 2002; 9: 423-32.
20. Slee EA, Harte MT, Kluck RM, et al. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2,--6,-7,-8 and -10 in a caspase-9-dependant manner. J Cell Biol 1999; 144: 281-92.
21. Guo Y, Srinivasula SM, Druilhe A, Fernandes-Alnemri, Alnemri ES. Caspase-2 induces apoptosis by releasing proapoptotic proteins from mitochondria. J Biol Chem 2002; 277: 13430-7.
22. Lassus P, Opitz-Araya X, Lazebnik Y. Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science 2002; 297: 1352-4.
23. Vakifahmetoglu H, Olsson M, Orrenius S, Zhivotovksky B. Functional connection between p53 and caspase-2 is essential for apoptosis induced by DNA damage. Oncogene 2006; 25: 5683-92.
24. Norbury CJ, Zhivotovsky B. DNA damage-induced apoptosis. Oncogene 2004; 23: 2797-808.
25. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998: 281: 1322-26.
26. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281: 1309-12.
27. Gross A, Jockel J, Wei MC, Korsmeyer SJ. Enforced dimerization of Bax results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J 1998; 17: 3878-85.
28. Chipuk JE. Mitochondrial outer membrane permeabilization during apoptosis: the innocent bystander scenario. Cell Death Differ 2006; 13: 1396-402.
29. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988; 335: 440-2.
30. Leber B. Embedded together: the life and death consequences of interaction of the Bcl-2 family with membranes. Apoptosis 2007; 12: 897-911.
31. Wei MC, Lindsten T, Mooth VK, et al. tBID, a transmembranetargeted death ligand, oligomerizes Bak to release cytochrome c. Genes Dev 2000; 14: 2060-71.
32. Youle RJ, Strasser A. The Bcl-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47-59.
33. Sattler M, Liang H, Nettesheim D, et al. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 1997; 275: 983-6.
34. Muchmore SW, Sattler M, Liang H, et al. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 1996; 381: 335-41.
35. Antonsson B, Conti F, Ciavatta A, et al. Inhibition of Bax channelforming activity by Bcl-2. Science 1997; 277: 370-2.
36. Minn AJ, Velez P, Schendel SL, et al. Bcl-x(L) forms an ion channel in synthetic lipid membranes. Nature (London) 1997; 385: 353-7.
37. Schendel SL, Xie Z, Montal MO, Matsuyama S, Montal M, Reed JC. Channel formation by antiapoptotic protein Bcl-2. Proc Natl Acad Sci USA 1997; 94: 5113-18.
38. Schlesinger PH, Gross A, Yin XM, et al. Comparison of the ion channel characteristics of proapoptotic BAX and antiapoptotic BCL-2. Proc. Natl Acad Sci USA 1997; 94: 11357-62.
39. Borner C, Martinou I, Mattman C. The protein Bcl-2 does not require membrane attachment, but two conserved domains to suppress apoptosis. J Cell Biol 1994; 126: 1059-68.
40. Hanada M, Aime-Sempe C, Sata T, Reed JC. Structurefunction analysis of Bcl-2 protein. Identification of conserved domains important for homodimerization with Bcl-2 and Hetrodimerization with Bax. J Biol Chem 1995; 270: 11962-9.
41. Huang DC, O'Reilly LA, Strasser A, Cory S. The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. EMBO J 1997; 16: 4628-38.
42. Shibasaki F, Kondo E, Akagi T, Mckeon F. Suppression of signaling through transcription factor NF-AT by interactions between calcineurin and Bcl-2. Nature 1997; 386: 728-31.
43. Wang HG, Rapp UR, Reed JC. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 1996; 87: 629-38.
44. Portier BP, Taglialatela G. Bcl-2 localized at the nuclear compartment induces apoptosis after transient over expression. J Biol Chem 2006; 281: 40493-502.
45. Reed JC. Double identity for proteins of the Bcl-2 family. Nature 1997; 387: 773-6.
46. Gross A, Yin XM, Wang K, Wei MC, Jockel J, Milliman C. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while Bcl-Xl prevents this release but not tumor necrosis factor-R1/Fas death, J Biol Chem 1999; 274: 1156-63.
47. Lei K, Davis RJ. JNK phosphorylation of Bim-related members of the Bcl-2 family induces Bax-dependent apoptosis. Proc Natl Acad Sci USA 2003; 100: 2432-7.
48. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not Bcl-Xl. Cell 1996; 87: 619-28.
49. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T. NOXA, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000; 288: 1053-8.
50. Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 2001; 7: 673-82.
51. Moldoveanu T, Liu Q, Tocilj A, Watson MH, Shore G, Gehring K. Mol Cell 2006; 24: 677-88.
52. Suzuki M, Youle RJ, Tjandra N. Structure of Bax: coregulation of dimer formation and intracellular localization. Cell 2000; 103: 645-54.
53. Yethon JA, Epand RF, Laber B, Epand RM, Andrews DW. Interaction with a membrane surface triggers a reversible conformational change in Bax normally associated with induction of apoptosis. J Biol Chem 2003; 278: 48935-41.
54. Huang DCS, Strasser A. The Bcl-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47-9.
55. Kelekar A, Thompson CB. Bcl2 family proteins: the role of BH3 domain in apoptosis. Trends Cell Biol 1998; 8: 324-30.
56. Letai A, Bassik M, Walensky L, Sorcinelli M, Weiler S, Korsmeyer S. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as protype cancer therapeutics. Cancer Cell 2002; 2: 183.
57. Kuwana T, Bouchier-Hayes L, Chipuk JE, et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 2005; 17: 525-35.
58. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007; 26: 1324-37.
59. Chen L, Willis SN, Wei A, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005; 17: 393-403.
60. Willis SN, Fletcher JI, Kaufmann T, et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not BAX or BAK. Science 2007; 315: 856-9.
61. Letai A, Sorcinelli MD, Beard C, Korsmeyer SJ. Anti-apoptotic Bcl-2 is required for maintenance of model leukemia. Cancer Cell 2004; 6: 241-9.
62. Cotter FE, Johnson P, Hall P, Pocock C, Al Mahadi N, Cowell JK. Antisense oligonucleotides suppress B-cell lymphoma growth in SCID-mouse model. Oncogene 1994; 9: 3049-55.
63. Emi M, Kim R, Tanabe K, Uchida Y, Toge T. Targeted therapy against Bcl-2 related proteins in breast cancer cells. Breast Cancer Res 2005; 7: R940-52.
64. Oltersdorf T, Elmore SW, Shoemaker AR. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-81.
65. Konopleva M, Contractor R, Tsao T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006; 10: 375-88.
66. Mason KD, Vandenberg CJ, Scott CL, et al. In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proc Natl Acad Sci USA 2008; 105: 17961-6.
67. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68: 3421-8.
68. Nguyen M, Marcellius RC, Roulston A, et al. Small molecule obatoclax (GX15-070) antagonizes Mcl-1 and overcomes Mcl-1 mediated resistance to apoptosis. Proc Natl Acad Sci USA 2007; 104: 19512-7.
69. Pérez-Galán P, Roué G, Villamor N, Campo E, Colomer D. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing NOXA-mediated activation of Bak. Blood 2007; 109: 4441-9.
70. Trudel S, Li ZH, Rauw J, Tiedmann RE, Wen XY, Stewart AK. Preclinical studies of the pan Bcl inhibitor obatoclax (GX15-070) in multiple myeloma. Blood 2007; 109: 5430-8.
71. Li J, Viallet J, Haura EB. A small molecule pan Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatininduced apoptosis in nonsmall cell lung cancer cells. Cancer Chemother Pharmacol 2007; 61: 525-34.
72. Wang JL, Liu D, Zhang ZJ. Structurebased discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA 2009; 97: 7124-9.
73. Manero F, Gautier F, Gallenne T. The small organic compound HA14-1 prevents Bcl-2 interaction with BAX to sensitize malignant glioma cells to induction of cell death. Cancer Res 2006; 66: 2757-64.
74. Oliver CL, Miranda MB, Shangary S, Land S, Wang S, Johnson DE. (-)-Gossypol acts directly on the mitochondria to overcome Bcl-2 and Bcl-XL-mediated apoptosis resistance. Mol Cancer Ther 2005; 4: 23-31.
75. Kitada S, Leone M, Sareth S, Zhai D, Reed JC, Pallecchia M. Discovery, characterization and structure-activity relationship studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia 2 proteins. J Med Chem 2003; 46: 4259-64.
76. Azmi AS, Mohammad RM. Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J Cell Physiol 2009; 218: 13-21.
77. Wang G, Nikolovska-Coleska Z, Yang CY. Structurebased design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem 2006; 49: 6139-42.
78. Wang GP. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem 2006; 49: 6139-42.
79. Tang GZ. Acylpyrogallols as inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem 2008; 51: 717-20.
80. Arnold AA. Preclinical studies of apogossypolone: a new nonpeptidic pan smallmolecular inhibitor of Bcl-2, Bcl-XL and Mcl-1proteins in follicular small cleaved cell lymphoma model. Mol Cancer 2008; 7: 20-30.
81. Herbert JM, Augereau JM, Gleye J, Maffrand JP. Biochem Biophys Res Commun 1990; 172: 993-9.